Absence Seizures
📧 Sign up to get email alerts when something new happens for Absence Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2010-10-11FDA Approved: CELONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for CELONTIN (methsuximide) submitted by Parke-Davis Div of Pfizer Inc.
-
FDA approval · 2010-09-14FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Zarontin (ethosuximide) submitted by Parke-Davis Div of Pfizer Inc. The approval relates to …
-
FDA approval · 2010-01-04FDA Approved: ETHOSUXIMIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA has approved a supplemental application for ethosuximide submitted by PAI Holdings/PAI Pharma.
-
FDA approval · 2009-12-10FDA Approved: ETHOSUXIMIDE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for Ethosuximide from Bionpharma Inc., confirming approval of the generic product.
-
FDA approval · 2009-11-20FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Zarontin (ethosuximide) filed by Parke-Davis Div of Pfizer Inc under ANDA080258.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2009-05-06FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Zarontin (ethosuximide) by Parke-Davis Div of Pfizer Inc, under the ANDA process.
-
FDA approval · 2009-04-23FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Zarontin (ethosuximide) from Parke-Davis (Pfizer). It updates the labeling for the product.
-
FDA approval · 2009-04-23FDA Approved: CELONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Celontin (methsuximide) from Parke-Davis Div of Pfizer Inc, expanding its labeling for epile…
-
FDA approval · 2008-03-03FDA Approved: ETHOSUXIMIDE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for Ethosuximide submitted by Bionpharma Inc. The action updates the regulatory filing for Ethosuxim…
-
FDA approval · 2006-10-03FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Zarontin (ethosuximide) submitted by Parke-Davis Div of Pfizer Inc, signaling an update to t…
-
FDA approval · 2006-09-01FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Zarontin (ethosuximide) submitted by Parke-Davis Div of Pfizer Inc.